Dr Gary Leigh Cohen, MD in Langley Afb, VA - Pathology

Dr Gary Leigh Cohen, MD is a Pathology - Anatomic Pathology & Clinical Pathology physician based in Langley Afb, Virginia. Dr Gary Leigh Cohen is licensed to practice in New York (license number 175518) and his current practice location is 45 Pine St, 1st Medical Group, Langley Afb, Virginia. He can be reached at his office (for appointments etc.) via phone at (757) 764-9534.

NPI number for Dr Gary Leigh Cohen is 1760452155 and his current mailing address is 45 Pine St, 1st Medical Group, Langley Afb, Virginia. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1760452155.

Contact Information

	Dr Gary Leigh Cohen, MD
	45 Pine St, 1st Medical Group, Langley Afb, VA 23665-2025
	(757) 764-9534
	(757) 764-6914

Physician's Profile

Full Name	Dr Gary Leigh Cohen
Gender	Male
Speciality	Pathology - Anatomic Pathology & Clinical Pathology
Location	45 Pine St, Langley Afb, Virginia
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1760452155
Provider Enumeration Date: 01/26/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Dr Gary Leigh Cohen such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1760452155	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207ZP0102X	Pathology - Anatomic Pathology & Clinical Pathology	175518 (New York)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Gary Leigh Cohen is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Gary Leigh Cohen, MD 45 Pine St, 1st Medical Group, Langley Afb, VA 23665-2025 Ph: (757) 764-9534	Dr Gary Leigh Cohen, MD 45 Pine St, 1st Medical Group, Langley Afb, VA 23665-2025 Ph: (757) 764-9534

News Archive

Probiotics show no benefit in preventing gastrointestinal colonization with drug-resistant microbes in ICU patients

Compared with routine medical care, probiotics administered to critically ill patients in intensive care units showed no benefit in preventing the colonization of drug-resistant microbes in the intestinal tract, according to new research at Washington University School of Medicine in St. Louis.

Robotic surgery does not compromise clinical outcomes for prostate cancer surgery

Robotic surgical technology with its three-dimensional, high-definition view gives surgeons the sensation of touch, even as they operate from a remote console. A new study describes the phenomenon, called intersensory integration, and reports that surgical outcomes for prostate cancer surgery using minimally invasive robotic technology compare favorably with traditional invasive surgery.

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

GHIT Fund makes new investments in potential treatments for malaria, tuberculosis and Chagas disease

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.

FDA-approved COVID-19 drug should be used cautiously, says UC researcher

While the world has its eyes on vaccines to stop the spread of coronavirus, therapeutics are still necessary to treat hospitalized patients. One of these treatments, remdesivir, is the first and only antiviral agent of its kind that the U.S. Food and Drug Administration (FDA) has approved so far for COVID-19.

Dr Gary Leigh Cohen, MD - Pathology in Langley Afb, VA